- Home
- CNTA vs MKTX Comparison
CNTA vs MKTX Comparison
Compare CNTA & MKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNTA | MKTX |
|---|---|---|
| Founded | 2020 | 2000 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.1B |
| IPO Year | 2021 | 2004 |
Fundamental Metrics
Financial Performance| Metric | CNTA | MKTX |
|---|---|---|
| Price | $39.62 | $141.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $43.17 | ★ $204.88 |
| AVG Volume (30 Days) | ★ 1.5M | 452.0K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.94% |
| EPS Growth | ★ 29.13 | N/A |
| EPS | N/A | ★ 2.20 |
| Revenue | $15,000,000.00 | ★ $397,471,000.00 |
| Revenue This Year | N/A | $10.14 |
| Revenue Next Year | N/A | $7.22 |
| P/E Ratio | ★ N/A | $63.00 |
| Revenue Growth | N/A | ★ 7.45 |
| 52 Week Low | $10.95 | $137.27 |
| 52 Week High | $40.26 | $228.16 |
Technical Indicators
Market Signals| Indicator | CNTA | MKTX |
|---|---|---|
| Relative Strength Index (RSI) | 71.86 | 31.18 |
| Support Level | $39.36 | N/A |
| Resistance Level | $39.86 | $178.87 |
| Average True Range (ATR) | 0.14 | 4.87 |
| MACD | -0.33 | -0.92 |
| Stochastic Oscillator | 50.50 | 18.29 |
Price Performance
Historical ComparisonAbout CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
About MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.